What should an RSO confirm before accepting Lu-177 for a therapy program?

Confirm the certificate of analysis for radionuclidic purity (including Lu-177m content), the specific or molar activity, the calibration date and time, and the applicable pharmacopeial limits. Then make sure the facility's waste procedures account for any long-lived Lu-177m, because that material may fall outside the ordinary decay-in-storage pathway.

Lu-177 Production: Carrier-Added vs n.c.a.

Q: What is the difference between carrier-added and non-carrier-added Lu-177?

Carrier-added (c.a.) Lu-177 is made directly by irradiating enriched Lu-176 in a reactor; the product contains stable lutetium carrier and has a lower specific activity. Non-carrier-added (n.c.a.) Lu-177 is made indirectly from enriched Yb-176, which decays to Lu-177 that is then chemically separated from the ytterbium, giving a product with essentially no stable lutetium carrier and a much higher specific activity.

Q: Why does Lu-177 production route matter clinically?

Higher specific activity (n.c.a.) lets more of the targeting molecules carry a radioactive atom, so fewer unlabeled 'cold' molecules compete for the same receptors. The route also determines whether the long-lived Lu-177m impurity is present, which affects radioactive-waste handling but not the individual patient treatment.

Q: What is Lu-177m and why is it a problem?

Lu-177m is a metastable nuclear isomer of lutetium with a physical half-life of about 160 days. It is co-produced mainly by the direct carrier-added route. Because its half-life far exceeds the 120-day limit for decay-in-storage under 10 CFR 35.92, waste containing meaningful Lu-177m cannot simply be held to decay on the usual nuclear-medicine timescale.

Q: Are Lutathera and Pluvicto carrier-added or non-carrier-added?

Both FDA-approved Lu-177 therapies — Lutathera (lutetium Lu 177 dotatate, approved 2018) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan, approved 2022) — are produced with non-carrier-added Lu-177 according to the nuclear-medicine production literature. The route is not stated on the FDA label itself.

Q: What specific activity can non-carrier-added Lu-177 reach?

The theoretical carrier-free specific activity of Lu-177 is about 4.1 TBq/mg (roughly 110 Ci/mg). Non-carrier-added product approaches this value, while carrier-added product is typically only on the order of 0.4 to 1.1 TBq/mg (about 10 to 30 Ci/mg) depending on the reactor neutron flux and irradiation time.

Q: Does carrier-added Lu-177 still work for therapy?

Yes. Carrier-added Lu-177 has been used successfully to prepare therapeutic doses, including Lu-177-PSMA-617, in hospital radiopharmacies. It requires more targeting ligand per unit activity and careful attention to radionuclidic purity and Lu-177m-related waste, but it remains a clinically viable supply route.

Introduction

Lutetium-177 can be produced two fundamentally different ways, and the production route — not the targeting molecule it is attached to — sets its specific activity, its long-lived Lu-177m impurity burden, and how its radioactive waste must be handled. For a theranostics program and its radiation safety officer, those three consequences shape labeling chemistry, dose logistics, and the waste that stays in the facility long after the patient has gone home.

Lu-177 has become one of the most important therapy radionuclides in nuclear medicine. It emits short-range beta particles that deposit therapeutic dose over about two millimeters of tissue, together with low-yield gamma photons at 113 keV and 208 keV that can be imaged on a gamma camera for post-therapy dosimetry. ¹ That combination — a therapeutic particle plus an imageable photon from the same atom — is exactly what makes Lu-177 a theranostic workhorse in peptide receptor radionuclide therapy (PRRT) and prostate-specific membrane antigen (PSMA) therapy.

What is less visible from the clinic is where the activity comes from. Two production routes dominate, and they are not interchangeable from a physics, chemistry, or radiation safety standpoint. This article explains the carrier-added and non-carrier-added routes, what each one does to specific activity and the Lu-177m impurity, and how those differences flow through to labeling, dosimetry, and radioactive-waste management. DRPS supports facilities building or expanding these programs through PET/CT and nuclear medicine physics and radioactive material license support across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What is Lu-177, physically?

Lu-177 decays by beta-minus emission with a physical half-life of about 6.6443 days. ⁸ The principal beta particle has a maximum energy near 498 keV, and the decay is accompanied by gamma photons at approximately 113 keV (about 6% emission probability) and 208 keV (about 11%). ^{1, 8} The beta is the therapy; the gammas are what let you image the biodistribution and perform patient-specific dosimetry after administration. For a broader survey of the therapy and imaging isotopes in this family, see Common PET & RPT isotopes.

None of that depends on how the Lu-177 was made. What does depend on the production route is how many stable, non-radioactive lutetium atoms ride along with each radioactive one, and whether a long-lived metastable form — Lu-177m — is present. Those two facts drive everything that follows.

Carrier-added versus non-carrier-added: the core distinction

There are two practical ways to produce Lu-177 for medicine. ^{2, 3}

Direct, carrier-added (c.a.): irradiate a target enriched in Lu-176 with reactor neutrons. The reaction Lu-176(n,γ)Lu-177 converts some of the Lu-176 to Lu-177. Because the target is lutetium and only a small fraction of atoms are activated, the product is a mixture of radioactive Lu-177 and a large excess of stable lutetium (unreacted Lu-176 plus Lu-175). That stable lutetium is the "carrier." ^{3, 4}
Indirect, non-carrier-added (n.c.a.): irradiate a target enriched in Yb-176. The reaction Yb-176(n,γ)Yb-177 produces Yb-177, which beta-decays with a roughly 1.9-hour half-life to Lu-177. Because lutetium and ytterbium are different elements, the newly formed Lu-177 can be chemically separated from the ytterbium target, yielding Lu-177 that is essentially free of stable lutetium carrier. ^{2, 3}

The language matters because "carrier-free" is a theoretical ideal; real n.c.a. product is "non-carrier-added," meaning no carrier was deliberately added and the stable-lutetium content is negligible. The distinction is not branding — it changes the number of radioactive atoms per microgram of lutetium by roughly two orders of magnitude.

Key Technical Principles

Comparing the two routes

Attribute	Carrier-added (direct)	Non-carrier-added (indirect)
Nuclear reaction	Lu-176(n,γ)Lu-177	Yb-176(n,γ)Yb-177 → β⁻ → Lu-177
Target element	Enriched lutetium (Lu-176)	Enriched ytterbium (Yb-176)
Stable Lu carrier	High (large stable-Lu excess)	Negligible
Typical specific activity	~0.4–1.1 TBq/mg (~10–30 Ci/mg), flux-dependent ^{4, 5}	Approaches theoretical max (~4.1 TBq/mg, ~110 Ci/mg) ³
Lu-177m co-production	Present (same element, same neutron field) ^{6, 7}	Essentially removed by Yb/Lu separation ^{2, 6}
Chemical processing	Minimal (no element change)	Requires Yb/Lu separation chemistry ^{2, 3}
Main radiation-safety wrinkle	Long-lived Lu-177m in waste ⁶	Higher-cost processing, supply chain

The numbers in the table are route-level starting points, not a substitute for the certificate of analysis that accompanies a specific batch. Specific activity in particular is strongly flux-dependent for the carrier-added route. ⁴

Specific activity, from first principles

Specific activity is activity per unit mass of the element. For a pure, carrier-free radionuclide it is set entirely by the decay constant and the atomic mass:

A_{sp} = \frac{λ N _{A}}{M} = \frac{ln 2 N _{A}}{T _{1/2} M}

For Lu-177, with $T_{1/2} = 6.6443 d = 5.74 \times 1 0^{5} s$ , $N_{A} = 6.022 \times 1 0^{23} mol^{- 1}$ , and $M = 177 g/mol$ :

λ = \frac{ln 2}{5.74 \times 1 0 ^{5} s} = 1.21 \times 1 0^{- 6} s^{- 1}

A_{sp} = \frac{( 1.21 \times 1 0 ^{- 6} ) ( 6.022 \times 1 0 ^{23} )}{177} \approx 4.1 \times 1 0^{15} Bq/g = 4.1 TBq/mg \approx 110 Ci/mg

That is the ceiling. Non-carrier-added Lu-177 approaches it. ³ Carrier-added Lu-177 cannot, because most of the lutetium mass is stable: reported carrier-added values cluster around 0.56–0.82 TBq/mg at research reactors and 0.66–0.81 TBq/mg (≈18–22 Ci/mg) in a hospital radiopharmacy preparation, depending on neutron flux and irradiation time. ^{4, 5} In other words, non-carrier-added product can deliver on the order of a hundred times more activity per microgram of lutetium than typical carrier-added product.

Radioactive decay and the half-life

The activity of any Lu-177 dose falls off as:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{6.6443 d} = 0.1043 d^{- 1}

A 7.4 GBq dose therefore decays to about 6.67 GBq after one day, to 3.70 GBq (half) after 6.6443 days, and to roughly 1.7 GBq after two weeks. The 6.6-day half-life is long enough to ship unit doses and perform multi-day post-therapy imaging, which is a large part of why Lu-177 is practical in routine clinical workflows. ¹

The Lu-177m problem

Lu-177 has a metastable nuclear isomer, Lu-177m, with a physical half-life of about 160.4 days. ^{6, 8} It is co-produced mainly by the direct, carrier-added route, because activating a lutetium target in a neutron field populates the isomer as well as the ground state. The non-carrier-added route essentially removes it: Lu-177m is a lutetium species, so it is separated out along with the bulk ytterbium chemistry only to the extent it was formed, and the indirect route forms very little. ^{2, 6}

In carrier-added product the amount is small relative to Lu-177 — reported Lu-177/Lu-177m activity ratios are on the order of several thousand (roughly 4,000–10,000), and specific-activity ratios of Lu-177m to Lu-177 at end of bombardment have been reported at or below about 0.025. ^{3, 7} That tiny fraction is clinically irrelevant to the individual treatment, but it is radiologically important downstream: a 160-day half-life does not meaningfully decay over the weeks that a nuclear-medicine department would normally hold waste. We return to that under Regulatory Considerations.

Clinical Impact

From the patient's side, the therapy is delivered by the Lu-177 beta regardless of route. Where the route shows up clinically is in molar activity — the activity per mole of the labeled targeting molecule.

With non-carrier-added Lu-177, a high fraction of the targeting molecules (a DOTATATE peptide, a PSMA ligand) can be labeled with a radioactive atom, so comparatively few unlabeled "cold" molecules are injected to compete for the same finite number of receptors. With lower-specific-activity carrier-added Lu-177, more total lutetium — and therefore more ligand — is required to carry the same activity, which can increase the mass of cold, competing molecules. For saturable receptor targets this is a real design consideration, and it is one reason the two FDA-approved agents use non-carrier-added material. ²

Those agents are Lutathera (lutetium Lu 177 dotatate), approved in 2018 for certain gastroenteropancreatic neuroendocrine tumors, and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), approved in 2022 for certain PSMA-positive metastatic castration-resistant prostate cancers. ^{11, 12} Both are produced with non-carrier-added Lu-177 according to the production literature, though the prescribing information itself does not specify the route. ^{2, 6} For the downstream dosimetry side of these treatments, see Lu-177 DOTATATE PRRT and Lu-177 PSMA therapy dosimetry and safety.

Carrier-added Lu-177 is not clinically inferior for every use. Hospital radiopharmacies have prepared multi-dose, ready-to-use Lu-177-PSMA-617 with carrier-added material at moderate specific activity and demonstrated good radiochemical purity and clinical response. ⁵ The route is an engineering and radiation-safety trade-off, not a verdict on efficacy.

Practical Optimization Tips

For a facility building or running a Lu-177 program, the production route turns into a short list of practical checks.

1. Read the certificate of analysis as a physics document

Every batch arrives with a certificate stating radionuclidic purity, specific (or molar) activity, and the calibration date and time. Confirm that the stated specific activity matches what the labeling chemistry assumes, and that radionuclidic purity — including any Lu-177m statement — is within the applicable pharmacopeial limit.

2. Decay-correct to the time of use

Because activity falls about 10% per day, always decay-correct the stated activity to your administration time using $A (t) = A_{0} e^{- λ t}$ . A dose assayed a day before use is not the dose you deliver.

3. Match ligand mass to specific activity

If you switch between a higher-specific-activity (n.c.a.) and lower-specific-activity (c.a.) supply, the mass of targeting ligand per unit activity changes. Re-verify the labeling ratio rather than assuming the old recipe transfers.

4. Segregate Lu-177m-bearing waste

Treat waste that may contain Lu-177m as a separate, long-lived stream. Do not fold it into the routine short-half-life decay-in-storage pile, where its 160-day half-life would quietly violate your hold-to-release assumptions. For the general framework, see radioactive waste management in nuclear medicine and decay-in-storage of radioactive waste.

5. Verify radiochemical as well as radionuclidic purity

Specific activity and Lu-177m are radionuclidic-purity questions. Separately confirm radiochemical purity (the fraction of activity on the intended molecule) with the appropriate assay; see radiochemical purity and TLC quality control.

Regulatory Considerations

Lu-177 is byproduct material, so its medical use is governed by NRC regulations — or the equivalent Agreement State rules — and its radioactive waste must be managed accordingly. Three frameworks matter most.

10 CFR Part 20 — Standards for Protection Against Radiation. This sets occupational and public dose limits, survey and labeling requirements, and the waste-disposal rules that a therapy program must satisfy. ¹⁰
10 CFR Part 35 — Medical Use of Byproduct Material. This governs authorized users, written directives, patient release, and the radiation safety program for therapy radionuclides such as Lu-177.
10 CFR 35.92 — Decay-in-storage. This is where the Lu-177m distinction becomes a compliance issue. Decay-in-storage lets a licensee hold byproduct material with a physical half-life less than or equal to 120 days until it has decayed, then dispose of it as ordinary waste after surveying. Lu-177 itself (6.6 days) is an easy fit. Lu-177m, at about 160 days, exceeds the 120-day threshold — so waste with meaningful Lu-177m content is not eligible for the ordinary decay-in-storage pathway and must be handled through another authorized route. ^{6, 10}

On top of the NRC framework, the drug product must meet the radionuclidic-purity limits of the applicable pharmacopeial monograph (for example, the European Pharmacopoeia or USP monograph for lutetium Lu-177 solutions), which constrains how much Lu-177m and other impurities a therapeutic preparation may contain. Published analyses of commercial and in-house Lu-177 have confirmed that product can comply with the pharmacopeial limit while still carrying enough Lu-177m to complicate waste release and sterility-testing logistics at the facility level. ⁶ Confirm the current monograph limit directly rather than working from memory.

Jurisdiction depends on the material. Lu-177 is radioactive (byproduct) material, so it is regulated by the NRC or an Agreement State — not by the FDA/state X-ray framework that governs imaging equipment. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license before relying on any waste or purity assumption. Coordinate the production-route decision with radioactive material license support and RSO program guidance.

Frequently Asked Questions (FAQs)

What is the difference between carrier-added and non-carrier-added Lu-177?

Carrier-added Lu-177 is made directly by irradiating enriched Lu-176, so it contains a large excess of stable lutetium and has lower specific activity. Non-carrier-added Lu-177 is made indirectly from Yb-176, then chemically separated from the ytterbium, leaving essentially no stable lutetium carrier and a much higher specific activity.

Why does the production route matter clinically?

Higher specific activity lets more targeting molecules carry a radioactive atom, so fewer unlabeled molecules compete for the same receptors. The route also determines whether the long-lived Lu-177m impurity is present, which affects waste handling rather than the individual treatment.

What is Lu-177m and why is it a problem?

Lu-177m is a metastable isomer of lutetium with a physical half-life of about 160 days, co-produced mainly by the carrier-added route. Because 160 days exceeds the 120-day limit for decay-in-storage under 10 CFR 35.92, waste containing meaningful Lu-177m cannot simply be held to decay on the usual nuclear-medicine timescale.

Are Lutathera and Pluvicto carrier-added or non-carrier-added?

Both are produced with non-carrier-added Lu-177 according to the production literature. The route is not stated on the FDA prescribing information itself.

What specific activity can non-carrier-added Lu-177 reach?

The theoretical carrier-free value is about 4.1 TBq/mg (roughly 110 Ci/mg), and non-carrier-added product approaches it. Carrier-added product is typically about 0.4 to 1.1 TBq/mg (about 10 to 30 Ci/mg), depending on reactor flux and irradiation time.

Does carrier-added Lu-177 still work for therapy?

Yes. Carrier-added Lu-177 has been used to prepare therapeutic Lu-177-PSMA-617 in hospital radiopharmacies with good radiochemical purity. It requires more ligand per unit activity and careful Lu-177m waste handling, but it remains clinically viable.

What should an RSO confirm before accepting Lu-177?

Confirm radionuclidic purity (including Lu-177m), specific or molar activity, and the calibration date and time on the certificate of analysis, and make sure waste procedures account for any long-lived Lu-177m that falls outside ordinary decay-in-storage.

Key Takeaways

The production route is a physics decision, not a label detail. It sets specific activity, the Lu-177m impurity, and the radioactive-waste profile.
Specific activity is capped at about 4.1 TBq/mg. Non-carrier-added Lu-177 approaches this ceiling; carrier-added is typically 0.4–1.1 TBq/mg because stable lutetium carrier dilutes it.
Lu-177m (about 160 days) is the carrier-added route's radiation-safety wrinkle. It is clinically negligible but exceeds the 120-day decay-in-storage limit, so its waste needs a separate pathway.
Both FDA-approved agents use non-carrier-added Lu-177. Higher molar activity reduces competition from unlabeled ligand at saturable receptors.
Carrier-added Lu-177 still treats patients effectively. The choice is an engineering and waste trade-off, not a statement about efficacy.
Document everything against the certificate of analysis and the pharmacopeial monograph — and confirm which regulator (NRC or Agreement State) licenses your program.

Conclusion

Lu-177 is a single radionuclide with two production biographies. The carrier-added route is chemically simple but delivers lower specific activity and brings the long-lived Lu-177m isomer along for the ride; the non-carrier-added route adds separation chemistry but delivers near-theoretical specific activity and essentially no Lu-177m. Neither is universally "better." What matters is that the physicist and the RSO understand which route supplied a given batch, confirm the specific activity and radionuclidic purity against the certificate and the pharmacopeial limit, and make sure the facility's waste procedures account for any Lu-177m that will not decay away on a nuclear-medicine timescale.

A theranostics program that treats production route as a documented input — not an invisible detail — is better positioned to label consistently, dose confidently, and keep its radioactive-waste program defensible during inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and theranostics programs translate radiopharmaceutical physics into practical, documented workflows. For Lu-177 therapy programs, this may include PET/CT and nuclear medicine physics support, dose-calibrator and radionuclidic-purity QC review, radioactive-waste and decay-in-storage program assessment, radioactive material license support, and RSO program guidance aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong theranostics program makes the safe, well-documented process the easy process for the clinical team.

Related Resources

References

Das T, Banerjee S. Theranostic Applications of Lutetium-177 in Radionuclide Therapy. Curr Radiopharm. 2016;9(1):94-101. doi:10.2174/1874471008666150313114644. doi.org (According to PubMed; PMID 25771364)
Vogel WV, van der Marck SC, Versleijen MWJ. Challenges and future options for the production of lutetium-177. Eur J Nucl Med Mol Imaging. 2021;48(8):2329-2335. doi:10.1007/s00259-021-05392-2. doi.org (According to PubMed; PMID 33974091)
Tarasov VA, Andreev OI, Romanov EG, et al. Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176. Curr Radiopharm. 2015;8(2):95-106. doi:10.2174/1874471008666150312160855. doi.org (According to PubMed; PMID 25771378)
Sairanbayev D, Koltochnik S, Shaimerdenov A, et al. Analysis of lutetium-177 production at the WWR-K research reactor. Appl Radiat Isot. 2020;169:109561. doi:10.1016/j.apradiso.2020.109561. doi.org (According to PubMed; PMID 33360502)
Chakraborty A, Mitra A, Tawate M, et al. Therapeutic Multidose Preparation of a Ready-to-Use Lu-177-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. Cancer Biother Radiopharm. 2021;36(8):682-692. doi:10.1089/cbr.2020.4261. doi.org (According to PubMed; PMID 34402687)
Balzer M, Spiecker F, Bluemel S, Amthauer H, Brenner W, Spreckelmeyer S. Evaluation of the Lu-177m-concentration in in-house produced Lu-177-radiopharmaceuticals and commercially available Lutathera. EJNMMI Radiopharm Chem. 2023;8(1):37. doi:10.1186/s41181-023-00222-2. doi.org (According to PubMed; PMID 37930495)
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Radionuclide generator-based production of therapeutic Lu-177 from its long-lived isomer Lu-177m. EJNMMI Radiopharm Chem. 2019;4(1):13. doi:10.1186/s41181-019-0064-5. doi.org (According to PubMed; PMID 31659496)
National Nuclear Data Center, Brookhaven National Laboratory. NuDat / Evaluated Nuclear Structure Data File (ENSDF): A = 177 (Lu-177, Lu-177m). nndc.bnl.gov
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
U.S. Nuclear Regulatory Commission. 10 CFR 35.92: Decay-in-storage. ecfr.gov
U.S. Food and Drug Administration. Lutathera (lutetium Lu 177 dotatate) prescribing information. 2018. accessdata.fda.gov
U.S. Food and Drug Administration. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) prescribing information. 2022. accessdata.fda.gov